Lyra Therapeutics (LYRA) officer returns 667 shares to issuer

Rhea-AI Filing Summary

Lyra Therapeutics Principal Financial Officer Jason Cavalier returned 667 shares of Common Stock to the company. The disposition to the issuer carried a reported price of $0.00 per share. After this transaction, he directly owns 517,880 shares, indicating this was a small, routine adjustment to his holdings.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cavalier Jason

Role Principal Financial Officer

Type	Security	Shares	Price	Value
Disposition	Common Stock	667	$0.00	--

Holdings After Transaction: Common Stock — 517,880 shares (Direct)

Footnotes (1)

Key Figures

Shares disposed: 667 shares Price per share: $0.00 per share Shares owned after transaction: 517,880 shares +1 more

4 metrics

Shares disposed 667 shares Common Stock disposition to issuer on 2026-04-01

Price per share $0.00 per share Reported for the 667-share disposition to issuer

Shares owned after transaction 517,880 shares Direct Common Stock holdings after Form 4 transaction

Non-derivative transactions 1 transaction Single Common Stock disposition reported in Form 4

Key Terms

Disposition to issuer, Common Stock, Form 4

3 terms

Disposition to issuer financial

"transaction code D is described as a Disposition to issuer"

Common Stock financial

"the security title for the transaction is Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 financial

"INSIDER FILING DATA (Form 4) summarizes the insider transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cavalier Jason

(Last) (First) (Middle)

C/O LYRA THERAPEUTICS, INC.

480 ARSENAL WAY

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyra Therapeutics, Inc. [ LYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		D		667	D	$0	517,880	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jason Cavalier	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Lyra Therapeutics (LYRA) report for Jason Cavalier?

Lyra Therapeutics reported that Principal Financial Officer Jason Cavalier disposed of 667 shares of Common Stock in a transaction classified as a disposition to the issuer. The transaction was reported at a price of $0.00 per share on Common Stock.

How many Lyra Therapeutics (LYRA) shares does Jason Cavalier hold after this Form 4?

After the reported transaction, Jason Cavalier directly owns 517,880 shares of Lyra Therapeutics Common Stock. This post-transaction balance shows his overall position remains substantial despite the relatively small issuer disposition of 667 shares reported in the filing.

What does the transaction code D mean in the Lyra Therapeutics (LYRA) Form 4?

The Form 4 lists transaction code D, described as a Disposition to issuer. This indicates shares were returned or transferred back to Lyra Therapeutics itself, rather than sold on the open market to outside investors or acquired through a typical purchase.

Was the Lyra Therapeutics (LYRA) insider transaction a market sale or purchase?

The transaction is categorized as a disposition to the issuer at a stated price of $0.00 per share, not as an open-market sale or purchase. It reflects a transfer of 667 shares back to Lyra Therapeutics instead of a trade with public investors.

Does the Lyra Therapeutics (LYRA) Form 4 show any derivative securities activity?

The filing’s derivative summary is empty, indicating no derivative security transactions such as option exercises or conversions were reported. The only activity disclosed is the non-derivative Common Stock disposition of 667 shares back to the issuer by Jason Cavalier.